The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

DSIP

Research chemical · Grade C

Goals
cognition, sleep
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Oxytocin

FDA-approved · Grade C

Goals
cognition, libido, hormonal
Evidence
10 RCT / 5 animal / 3 in vitro
Routes
injectable-sc, injectable-im, nasal
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
plasma half-life approximately 1-6 minutes (rapidly degraded by oxytocinases, primarily cystyl aminopeptidase/leucyl-cystinyl aminopeptidase)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

VIP

Research chemical · Grade C

Goals
cognition, gut, immune
Evidence
2 RCT / 5 animal / 4 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Epitalon

Bioregulator · Grade C

Goals
cognition, sleep, longevity
Evidence
0 RCT / 5 animal / 3 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →